By Katherine Hamilton
Repare Therapeutics plans to find a partner before moving forward with developing a possible treatment for cancer as it aims to extend its cash runway into 2027.
The oncology company said Thursday it will find a partner before it proceeds with planned and regulatory-supported pivotal development of lunresertib and camonsertib, which together are meant to treat gynecological cancer.
Repare is also reorganizing its resources and clinical portfolio to focus on advancing the Phase 1 clinical programs of its tumor treatments RP-1664 and RP-3467.
Savings from late-stage clinical funding and planned layoffs are expected to extend the company's cash runway into the mid-2027, the company said.
In August, Repare said it planned to cut about a quarter of its workforce as part of strategic move to refocus efforts on its lunresertib, camonsertib, RP-1664 and RP-3467 products. It anticipated the layoffs will generate about $15 million in annual savings.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
January 09, 2025 17:00 ET (22:00 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。